Scientists have discovered a new crucial molecule that may help treat liver issues and obesity.

A recent preclinical study conducted by experts from Weill Cornell Medicine and the Boyce Thompson Institute at Cornell University has revealed a complex relationship between the human body and beneficial gut microbes in regulating fat metabolism and cholesterol levels. These mechanisms, it turns out, impact crucial aspects of our metabolism, which scientists may utilize to develop new effective medications, as reported by News Medical.

The research, published in the journal Nature Communications, demonstrated how this interaction influences the production of bile acids, which are essential for fat digestion and metabolic processes.

Researchers have long known that gut microbes assist in the breakdown of bile acids, which are synthesized from cholesterol in the liver and play a vital role in fat digestion. These acids also serve as signaling molecules, interacting with the FXR receptor and regulating cholesterol metabolism and bile production.

In the new study, scientists identified a novel molecule, bile acid methylcysteamine (BA-MCY), produced by intestinal cells, which counteracts the FXR-stimulating effect of modified bile acids. This mechanism ensures a balance in bile production, preventing metabolic dysregulation.

Dr. David Artis, director of Weill Cornell Medicine, emphasized the dialogue between gut microbes and the host as a crucial tool in regulating bile acid production. Dr. Frank Schroeder, a co-author of the study, highlighted the broader role of bile acids beyond digestion, noting their function in overall metabolic signaling within the body. The interdisciplinary approach of the researchers employed untargeted metabolomics to isolate molecules produced by the host that depend on the presence of microorganisms.

BA-MCY emerged as critical elements in maintaining this balance, with their production influenced by dietary factors such as fiber intake. The findings also hold promising implications for future methods of supporting and enhancing human health. For instance, researchers demonstrated that elevated levels of BA-MCY in preclinical models reduce fat accumulation in the liver, and dietary fiber consumption increases BA-MCY production.

Dr. Mohammad Arifuzzaman noted that this data could serve as a foundation for treating conditions such as fatty liver disease and obesity. Future studies aim to investigate the regulation of host-microbe interactions in various diseases, from chronic inflammation to cancer. This research not only lays the groundwork for understanding the role of gut microbiota in health but also underscores the potential of dietary interventions in managing overall metabolic health.

This material is for informational purposes only and does not contain advice that may affect your health. If you are experiencing issues, please consult a specialist.